PRTC

PureTech Health PLC

Add to Watchlist

Advanced Chart

16.590

-0.759(-4.380%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

17.240

Open

17.190

VWAP

17.18

Vol

3.08K

Mkt Cap

398.47M

Low

16.520

Amount

52.84K

EV/EBITDA(TTM)

Total Shares

23.93M

42.90M

EV/OCF(TTM)

P/S(TTM)

95.84

PureTech Health plc is a clinical stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.

1 Analyst Rating

177.28% Upside

Wall Street analysts forecast PRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRTC is 46.00 USD with a low forecast of 46.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

177.28% Upside

Current: 16.590

Low

46.00

Averages

46.00

High

46.00

177.28% Upside

Current: 16.590

Low

46.00

Averages

46.00

High

46.00

Leerink Partners

Faisal Khurshid

Buy

Initiates

$45

2024-09-09

Reason

Leerink Partners

Faisal Khurshid

Price Target

$45

2024-09-09

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for PureTech Health PLC (PRTC.O) is -4.05, compared to its 5-year average forward P/E of -5.60. For a more detailed relative valuation and DCF analysis to assess PureTech Health PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.60

Current PE

-4.05

Overvalued PE

-2.66

Undervalued PE

-8.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.97

Current EV/EBITDA

-1.26

Overvalued EV/EBITDA

-1.22

Undervalued EV/EBITDA

-6.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

75.11

Current PS

15.02

Overvalued PS

122.42

Undervalued PS

27.79